Business News • PR NewsWire • MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

SAN DIEGO, June 22, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced that updated data presented in an oral presentation at ICML 2019 from a Phase 1b study of investigational...

View More : https://www.prnewswire.com:443/news-releases/mei-pharma-presents-updated-clinical-data-from-the-me-401-phase-1b-study-in...

Releted News by prnewswire

Eyewear Market Share Will Grow at 5% CAGR to Cross US$170bn by 2025: GMI

Casablanca y Toronto impulsan la colaboración mundial de los servicios financieros

iQIYI Launches the First Domestic Interactive Film and Television Work "His Smile", Providing Brand New User Experience to the Chinese Audience

MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

Buddhist Master Jun Hong Lu Invited to Give Keynote Speech at Vesak Day Commemoration at UNESCO

GP Transco Secures Third Crain's Fast 50 Listing

Safe-T Launches Exclusive SDP Cloud Service